Breaking News

5 powerful people to know at HHS

February 19, 2026
john-wilkerson-avatar-teal
Washington Correspondent, D.C. Diagnosis Writer

Dr. Oz said your poop "should gently hit the water like Greg Louganis diving in." In other news, the Potomac, threatened by one of the largest sewage spills in U.S. history, has been informally renamed. Send news tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal, but keep fecal news to yourself. I've had enough.

congress

The transience of Trump's MFN deals

The White House wants to codify in law the voluntary deals between drugmakers and the Trump administration on lowered prices, CMS Administrator Mehmet Oz said Tuesday at the annual PhRMA Forum.

Daniel Payne had already told you that Trump administration officials met with Republican senators to push for most-favored nation drug pricing legislation. Sources also say the administration has been pressing House Energy and Commerce Chair Brett Guthrie (R-Ky.) on that issue. However, Republicans don't seem receptive to the idea.

Oz framed the policy as a way to prevent future administrations from abusing Trump's deals and lowering prices even further, an odd case to make after President Trump said those deals are "the largest reduction in prescription drug prices in history by many many times, and it's not even close."

Industry isn't buying it.

"It's one thing to have these individual, voluntary agreements," PhRMA President Stephen Ubl said. "It's quite another to enshrine in statute essentially a dial that only moves in one direction."

Oz obliquely mentioned one more plausible reason for seeking to codify Trump's drug pricing deals when he said that TrumpRx relies on the deals having "some longevity." The deals, details of which still haven't been released, could evaporate the moment Trump leaves office.



HHS

5 HHS officials to watch this year

Chelsea Cirruzzo runs down the new team of health policy experts charged with driving the more politically popular aspects of the MAHA agenda. (Read, not vaccines.)

In addition to playing up policy "wins," such as healthy food and drug pricing, the new direction for HHS after last week's shake-up is an attempt to smooth over dysfunction at the agencies.

The new team includes a former health IT exec and a Trump administration veteran. Read more to find out who is on the A Team and who has been benched.


vaccines

Vinay Prasad overruled

The FDA is going to review Moderna's application for a new mRNA flu vaccine after all, Lizzy Lawrence reports.

Last week, the agency refused to review the submission. FDA career scientists wanted to accept the application, but biologics center director Vinay Prasad overruled them, Lizzy scooped last week.

Keep in mind, the FDA hadn't refused to approve the vaccine; it was refusing to review the application for approval, even though the FDA had okayed the approach to testing.

That rejection led industry to question whether they could trust the FDA. It also put vaccines in the spotlight right as the administration tries to shift attention toward drug pricing and food policies.

Read more.


pharma

Unequal treatment

The day before the FDA's reversal, Commissioner Marty Makary was grilled about the agency's handling of Moderna's flu vaccine application at the PhRMA Forum.

Makary had a much different reception than Oz, Lizzy and Daniel Payne report. Makary was given the third degree by former CNBC reporter Bertha Coombs, while Oz fielded softball questions from Pfizer CEO and PhRMA board chair Albert Bourla.

The contrast illustrated industry's seemingly positive relationship with Oz and its strained relationship with Makary. Read more.


vaccine advisers

ACIP meeting might be postponed

Federal officials have missed the legal deadline to notify the public of an upcoming meeting of a vaccine advisory panel that was planned for next week, Chelsea reports.

This is the kind of thing that makes it difficult to shift attention from the administration's work to undermine vaccines. The health care community was expected to closely monitor the meeting, one of three regularly held each year, for signs of what the Trump administration might do next on Covid-19 vaccines and other mRNA-based immunizations.

It's not been officially postponed yet, but the missed deadline raises questions. Read more.


cdc

Double duty

NIH Director Jay Bhattacharya will also be the acting CDC director, Chelsea and Anil Oza report.

He'll take over from Jim O'Neill, who will be nominated to run the National Science Foundation.

By law, the post isn't supposed to be held by an acting official past March 25, though Bhattacharya could remain in the role during the confirmation process for a new director. Trump hasn't nominated a permanent CDC director, and it's possible that there will not be a full-time director for the rest of Trump's term.


stat

Tooting our own horn

STAT co-founder and Executive Editor Rick Berke wrote this note about STAT winning its fourth George Polk Award.

The Polk Award goes to Lizzy – go Lizzy! – for documenting the Trump administration's shakeup of the FDA. It also recognizes journalists across STAT for, among other achievements, the 10-part series "American Science, Shattered," and the 17-part "MAHA Diagnosis."

Shameless suck-up: Our editors deserve a lot of credit, too, and if you're reading this sentence, it means my editor didn't strike it. No other news outlet our size has been so frequently honored in recent history.


h-1b visas

100

That's how many lawmakers signed a bipartisan, bicameral letter urging Department of Homeland Security Secretary Kristi Noem to grant a health care sector exemption from the $100,000 fee for new H-1B visas.

They say the exemption is needed to mitigate health care workforce shortages, especially at rural and urban safety-net hospitals. Nearly 87 million Americans live in areas without sufficient medical professionals, according to the Health Resources and Services Administration. More than 20 million Americans live in areas where foreign-trained physicians account for at least half of all practicing doctors.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • The FDA's Moderna pirouette is one more sign of chaos at the agency, STAT
  • Documenting a 'drastically changing' scientific landscape, The New York Times
  • Proposed $7.25B settlement to resolve weedkiller cancer lawsuits, STAT
  • Measles is spreading in South Carolina. Could it make people vote for a pediatrician, The 19th

Thanks for reading! More next time,


Enjoying D.C. Diagnosis? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments